Vertex Pharmaceuticals Incorporated $VRTX Stock Acquired by Vise Technologies Inc.

Vise Technologies Inc. lifted its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 18.5% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 9,344 shares of the pharmaceutical company’s stock after buying an additional 1,462 shares during the period. Vise Technologies Inc.’s holdings in Vertex Pharmaceuticals were worth $4,885,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in VRTX. Grandfield & Dodd LLC raised its position in Vertex Pharmaceuticals by 3.4% during the third quarter. Grandfield & Dodd LLC now owns 25,689 shares of the pharmaceutical company’s stock valued at $13,430,000 after purchasing an additional 851 shares during the period. Global Assets Advisory LLC increased its position in shares of Vertex Pharmaceuticals by 5.7% during the 3rd quarter. Global Assets Advisory LLC now owns 2,145 shares of the pharmaceutical company’s stock valued at $1,077,000 after purchasing an additional 115 shares during the last quarter. Summit Global Investments increased its position in shares of Vertex Pharmaceuticals by 39.0% during the 3rd quarter. Summit Global Investments now owns 9,982 shares of the pharmaceutical company’s stock valued at $5,219,000 after purchasing an additional 2,800 shares during the last quarter. Invera Wealth Advisors LLC increased its position in Vertex Pharmaceuticals by 5.3% during the third quarter. Invera Wealth Advisors LLC now owns 871 shares of the pharmaceutical company’s stock valued at $455,000 after acquiring an additional 44 shares during the last quarter. Finally, Americana Partners LLC grew its holdings in Vertex Pharmaceuticals by 3.5% during the 3rd quarter. Americana Partners LLC now owns 40,295 shares of the pharmaceutical company’s stock valued at $21,067,000 after purchasing an additional 1,381 shares during the last quarter. 90.96% of the stock is currently owned by hedge funds and other institutional investors.

Vertex Pharmaceuticals Stock Down 4.0%

NASDAQ:VRTX opened at $530.76 on Wednesday. Vertex Pharmaceuticals Incorporated has a 52 week low of $403.16 and a 52 week high of $568.67. The firm has a 50 day moving average of $522.98 and a 200 day moving average of $480.37. The stock has a market capitalization of $134.71 billion, a price-to-earnings ratio of 34.15, a PEG ratio of 2.65 and a beta of 0.28.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Monday, November 2nd. The pharmaceutical company reported $4.76 earnings per share for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.06). The business had revenue of $3.44 billion during the quarter, compared to analyst estimates of $3.42 billion. Vertex Pharmaceuticals had a return on equity of 22.40% and a net margin of 30.70%. The firm’s revenue for the quarter was up 11.8% compared to the same quarter last year. During the same period in the previous year, the business earned $4.80 EPS. As a group, analysts expect that Vertex Pharmaceuticals Incorporated will post 16.74 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Scotiabank raised their target price on shares of Vertex Pharmaceuticals from $558.00 to $660.00 and gave the stock a “sector outperform” rating in a research report on Tuesday. The Goldman Sachs Group increased their target price on Vertex Pharmaceuticals from $654.00 to $725.00 and gave the company a “buy” rating in a research report on Tuesday. Morgan Stanley cut their price target on Vertex Pharmaceuticals from $665.00 to $660.00 and set an “overweight” rating on the stock in a report on Tuesday. Weiss Ratings raised Vertex Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday, October 16th. Finally, Evercore upped their price objective on Vertex Pharmaceuticals from $535.00 to $600.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 2nd. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, Vertex Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $596.11.

Key Vertex Pharmaceuticals News

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Third-quarter revenue rose 11.8% year over year to $3.44 billion, topping estimates, supported by Vertex’s cystic-fibrosis franchise and growth from newer medicines including CASGEVY and JOURNAVX. The company also raised its 2026 sales outlook. Read More.
• Positive Sentiment: Management expressed confidence in the anticipated launch of povetacicept for IgA nephropathy ahead of an FDA decision, an important potential growth driver beyond cystic fibrosis. Several analysts also raised their price targets after the results. Read More. · Read More.
• Negative Sentiment: Adjusted earnings of $4.76 per share fell short of estimates. Acquisition and launch-related spending weighed on profit, while sales of the newer pain drug JOURNAVX were described as light—dampening the market’s reaction to the revenue beat. Read More.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.

Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.